ReviewInternational journal of nanomedicine2021
Bioresponsive Functional Phenylboronic Acid-Based Delivery System as an Emerging Platform for Diabetic Therapy.
Review in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Adaptable Covalent Organic Framework-Hydrogel Microneedles for Glucose-Responsive Isoliquiritigenin Delivery in Diabetic Wound Therapy.Advanced healthcare materials · 2026Article
- Edaravone-based precision antioxidative therapy alleviates intervertebral disc degeneration via the Nrf2/Aldh3a1 axis.Materials today. Bio · 2026Article
- Smart nanomaterials enabling drug delivery and glucose monitoring for diabetes management.Discover nano · 2026Review
- Dynamic glucose-responsive mesoporous silica nanoparticle coating on trabecular tantalum implants for dual mode drug delivery.Materials today. Bio · 2026Article
- An engineering-reinforced extracellular vesicle-integrated hydrogel with an ROS-responsive release pattern mitigates spinal cord injury.Science advances · 2025Article
- Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Stimuli-Responsive Hydrogels for Protein Delivery.Gels (Basel, Switzerland) · 2023Review
- Microneedle-based insulin transdermal delivery system: current status and translation challenges.Drug delivery and translational research · 2022Review
- Carbon Dots Embedded Hybrid Microgel with Phenylboronic Acid as Monomer for Fluorescent Glucose Sensing and Glucose-Triggered Insulin Release at Physiological pH.Nanomaterials (Basel, Switzerland) · 2022Article
- Interactions between Nanoparticles and Intestine.International journal of molecular sciences · 2022Review
- Novel glucose-responsive nanoparticles based on p-hydroxyphenethyl anisate and 3-acrylamidophenylboronic acid reduce blood glucose and ameliorate diabetic nephropathy.Materials today. Bio · 2022Article
- Multivesicular Liposomes for Glucose-Responsive Insulin Delivery.Pharmaceutics · 2021Article
- Nanoparticles prepared from pterostilbene reduce blood glucose and improve diabetes complications.Journal of nanobiotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The glucose-sensitive self-adjusting drug delivery system simulates the physiological model of the human pancreas-secreting insulin and then precisely regulates the release of hypoglycemic drugs and controls the blood sugar. Thus, it has good application prospects in the treatment of diabetes. Presently, there are three glucose-sensitive drug systems: phenylboronic acid (PBA) and its derivatives, concanavalin A (Con A), and glucose oxidase (GOD). Among these, the glucose-sensitive polymer carrier based on PBA has the advantages of better stability, long-term storage, and reversible glucose response, and the loading of insulin in it can achieve the controlled release of drugs in the human environment. Therefore, it has become a research hotspot in recent years and has been developed very rapidly. In order to further carry out a follow-up study, we focused on the development process, performance, and application of PBA and its derivatives-based glucose-sensitive polymer drug carriers, and the prospects for the development of this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.